• Publications
  • Influence
Antiulcer effect of geranylgeranylacetone, a new acyclic polyisoprenoid on experimentally induced gastric and duodenal ulcers in rats.
TLDR
There is a high possibility that GGA is useful for clinical treatment of peptic ulcers, probably through a mechanism of increasing defence force of the gastric mucosa.
Effects of the antiulcer drug geranylgeranylacetone on aspirin-induced gastric ulcers in rats.
TLDR
It was concluded that the protective actions of GGA on aspirin-induced gastric ulcers might be due to its protection from the weakening of gastric mucosal resistances.
[Inhibitory action of E3810 on H+,K(+)-ATPase and gastric acid secretion in vitro].
TLDR
The results suggest that the acid-activated E3810 is a potent specific inhibitor of H+,K(+)-ATPase, and that the duration of the inhibitory action of E 3810 is much shorter than that of omeprazole in isolated gastric glands.
[Effects of E-3123, a new protease inhibitor, on several protease activities and on experimental acute pancreatitis].
TLDR
The results show that E-3123 may possess suppressing effects on pathogenesis and development of acute pancreatitis and in dogs with pancreatitis, increases in serum trypsin and lipase activities were significantly reduced by infusion of E- 3123.
Effect of geranylgeranylacetone on aspirin-induced changes in gastric glycoproteins.
TLDR
The results indicated that the glycoproteins coating the surface of the gastric mucosa may play a role as a defensive mechanism and that GGA exerted an antiulcer effect on aspirin-induced mucosal damage through preventing the decreases in gastric glycoproteinins.
Effects of the Proton Pump Inhibitor, E3810, on Gastric Secretion and Gastric and Duodenal Ulcers or Erosions in Rats
TLDR
At low doses, E3810 was significantly more effective than omeprazole, but at high doses, there was no significant difference between the 2 drugs in efficacy.
...
1
2
3
4
5
...